COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say – Friedreich’s Ataxia News

Denise Cloutier, lab manager at the University of Florida’s Powell Gene Therapy Center, prepares a DNA sample for testing. (Photo by Larry Luxner)


While the ongoing COVID-19 pandemic won’t have much of an impact on cash available for new biotech startups, it has begun to cause delays in the development of gene therapies to treat a variety of rare diseases.

That’s the consensus of industry experts who spoke in a May 26 webinar hosted by the events organizer Terrapinn, producer of the annual World Orphan Drug Congress.

Click here to read full article

Font Resize